

Florian Kurth

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4218909/publications.pdf>

Version: 2024-02-01

81
papers

8,316
citations

101384

36
h-index

71532

76
g-index

107
all docs

107
docs citations

107
times ranked

15917
citing authors

#	ARTICLE	IF	CITATIONS
1	Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment. <i>Cell</i> , 2020, 182, 1419-1440.e23.	13.5	1,162
2	SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. <i>Nature</i> , 2020, 587, 270-274.	13.7	1,115
3	COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis. <i>Nature Biotechnology</i> , 2020, 38, 970-979.	9.4	887
4	Ultra-High-Throughput Clinical Proteomics Reveals Classifiers of COVID-19 Infection. <i>Cell Systems</i> , 2020, 11, 11-24.e4.	2.9	439
5	Estimating infectiousness throughout SARS-CoV-2 infection course. <i>Science</i> , 2021, 373, .	6.0	389
6	mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. <i>Nature Medicine</i> , 2022, 28, 477-480.	15.2	342
7	A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model. <i>Cell</i> , 2020, 183, 1058-1069.e19.	13.5	305
8	Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1255-1265.	5.2	279
9	SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis. <i>Cell</i> , 2021, 184, 6243-6261.e27.	13.5	277
10	Cross-reactive CD4 ⁺ T cells enhance SARS-CoV-2 immune responses upon infection and vaccination. <i>Science</i> , 2021, 374, eabh1823.	6.0	221
11	Ultra-fast proteomics with Scanning SWATH. <i>Nature Biotechnology</i> , 2021, 39, 846-854.	9.4	173
12	Untimely TGF β 2 responses in COVID-19 limit antiviral functions of NK cells. <i>Nature</i> , 2021, 600, 295-301.	13.7	146
13	Early IFN- γ signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19. <i>Immunity</i> , 2021, 54, 2650-2669.e14.	6.6	145
14	Recognition of microbial viability via TLR8 drives TFH cell differentiation and vaccine responses. <i>Nature Immunology</i> , 2018, 19, 386-396.	7.0	139
15	Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19. <i>Nature Biotechnology</i> , 2021, 39, 705-716.	9.4	129
16	A time-resolved proteomic and prognostic map of COVID-19. <i>Cell Systems</i> , 2021, 12, 780-794.e7.	2.9	125
17	Complement activation induces excessive T cell cytotoxicity in severe COVID-19. <i>Cell</i> , 2022, 185, 493-512.e25.	13.5	122
18	Fixed-Dose Pyronaridine-Artesunate Combination for Treatment of Uncomplicated Falciparum Malaria in Pediatric Patients in Gabon. <i>Journal of Infectious Diseases</i> , 2008, 198, 911-919.	1.9	91

#	ARTICLE	IF	CITATIONS
19	Adolescence As Risk Factor for Adverse Pregnancy Outcome in Central Africa – A Cross-Sectional Study. <i>PLoS ONE</i> , 2010, 5, e14367.	1.1	80
20	Studying the pathophysiology of coronavirus disease 2019: a protocol for the Berlin prospective COVID-19 patient cohort (Pa-COVID-19). <i>Infection</i> , 2020, 48, 619-626.	2.3	79
21	Schistosomiasis in European Travelers and Migrants: Analysis of 14 Years TropNet Surveillance Data. <i>American Journal of Tropical Medicine and Hygiene</i> , 2017, 97, 567-574.	0.6	69
22	Delayed Antibody and T-Cell Response to BNT162b2 Vaccination in the Elderly, Germany. <i>Emerging Infectious Diseases</i> , 2021, 27, 2174-2178.	2.0	67
23	Long-term immunogenicity of BNT162b2 vaccination in older people and younger health-care workers. <i>Lancet Respiratory Medicine</i> , 2021, 9, e104-e105.	5.2	65
24	Severity of respiratory failure and computed chest tomography in acute COVID-19 correlates with pulmonary function and respiratory symptoms after infection with SARS-CoV-2: An observational longitudinal study over 12 months. <i>Respiratory Medicine</i> , 2022, 191, 106709.	1.3	63
25	A serum proteome signature to predict mortality in severe COVID-19 patients. <i>Life Science Alliance</i> , 2021, 4, e202101099.	1.3	62
26	Severe malaria in Europe: an 8-year multi-centre observational study. <i>Malaria Journal</i> , 2017, 16, 57.	0.8	57
27	RNAemia Corresponds to Disease Severity and Antibody Response in Hospitalized COVID-19 Patients. <i>Viruses</i> , 2020, 12, 1045.	1.5	53
28	Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis. <i>Frontiers in Immunology</i> , 2021, 12, 690698.	2.2	52
29	Increased risk of severe clinical course of COVID-19 in carriers of HLA-C*04:01. <i>EClinicalMedicine</i> , 2021, 40, 101099.	3.2	52
30	Disease Severity, Fever, Age, and Sex Correlate With SARS-CoV-2 Neutralizing Antibody Responses. <i>Frontiers in Immunology</i> , 2020, 11, 628971.	2.2	51
31	Evaluation of PEEP and prone positioning in early COVID-19 ARDS. <i>EClinicalMedicine</i> , 2020, 28, 100579.	3.2	49
32	CD169/SIGLEC1 is expressed on circulating monocytes in COVID-19 and expression levels are associated with disease severity. <i>Infection</i> , 2021, 49, 757-762.	2.3	47
33	Sentinel surveillance of imported dengue via travellers to Europe 2012 to 2014: TropNet data from the DengueTools Research Initiative. <i>Eurosurveillance</i> , 2017, 22, .	3.9	46
34	Detailed stratified GWAS analysis for severe COVID-19 in four European populations. <i>Human Molecular Genetics</i> , 2022, 31, 3945-3966.	1.4	46
35	Do paediatric drug formulations of artemisinin combination therapies improve the treatment of children with malaria? A systematic review and meta-analysis. <i>Lancet Infectious Diseases</i> , 2010, 10, 125-132.	4.6	42
36	SARS-CoV-2 Proteome-Wide Analysis Revealed Significant Epitope Signatures in COVID-19 Patients. <i>Frontiers in Immunology</i> , 2021, 12, 629185.	2.2	42

#	ARTICLE	IF	CITATIONS
37	Plasma mediators in patients with severe COVID-19 cause lung endothelial barrier failure. <i>European Respiratory Journal</i> , 2021, 57, 2002384.	3.1	40
38	Hemolysis after Oral Artemisinin Combination Therapy for Uncomplicated <i>Plasmodium falciparum</i> Malaria. <i>Emerging Infectious Diseases</i> , 2016, 22, 1381-1386.	2.0	39
39	Pharmacokinetics of two paediatric artesunate mefloquine drug formulations in the treatment of uncomplicated falciparum malaria in Gabon. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 60, 1091-1096.	1.3	38
40	Intravenous Artesunate Reduces Parasite Clearance Time, Duration of Intensive Care, and Hospital Treatment in Patients With Severe Malaria in Europe: The TropNet Severe Malaria Study: Figure 1.. <i>Clinical Infectious Diseases</i> , 2015, 61, 1441-1444.	2.9	38
41	In vitro activity of pyronaridine against <i>Plasmodium falciparum</i> and comparative evaluation of anti-malarial drug susceptibility assays. <i>Malaria Journal</i> , 2009, 8, 79.	0.8	37
42	High prevalence of dhfr triple mutant and correlation with high rates of sulphadoxine-pyrimethamine treatment failures in vivo in Gabonese children. <i>Malaria Journal</i> , 2011, 10, 123.	0.8	35
43	Altered fibrin clot structure and dysregulated fibrinolysis contribute to thrombosis risk in severe COVID-19. <i>Blood Advances</i> , 2022, 6, 1074-1087.	2.5	35
44	Prospective evaluation of artemether-lumefantrine for the treatment of non-falciparum and mixed-species malaria in Gabon. <i>Malaria Journal</i> , 2012, 11, 120.	0.8	34
45	A proteomic survival predictor for COVID-19 patients in intensive care. , 2022, 1, e0000007.		28
46	Durability of omicron-neutralising serum activity after mRNA booster immunisation in older adults. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 445-446.	4.6	28
47	Clinical and virological characteristics of hospitalised COVID-19 patients in a German tertiary care centre during the first wave of the SARS-CoV-2 pandemic: a prospective observational study. <i>Infection</i> , 2021, 49, 703-714.	2.3	27
48	Efficacy and safety of a new pediatric artesunate-mefloquine drug formulation for the treatment of uncomplicated falciparum malaria in Gabon. <i>Wiener Klinische Wochenschrift</i> , 2010, 122, 173-178.	1.0	22
49	A Dual-Antigen Enzyme-Linked Immunosorbent Assay Allows the Assessment of Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Seroprevalence in a Low-Transmission Setting. <i>Journal of Infectious Diseases</i> , 2021, 223, 10-14.	1.9	21
50	Pyronaridine-artesunate combination therapy for the treatment of malaria. <i>Current Opinion in Infectious Diseases</i> , 2011, 24, 564-569.	1.3	19
51	Outbreak of SARS-CoV-2 B.1.1.7 Lineage after Vaccination in Long-Term Care Facility, Germany, February-March 2021. <i>Emerging Infectious Diseases</i> , 2021, 27, 2169-2173.	2.0	17
52	Early and Rapid Identification of COVID-19 Patients with Neutralizing Type I Interferon Auto-antibodies. <i>Journal of Clinical Immunology</i> , 2022, 42, 1111-1129.	2.0	17
53	A multiplex protein panel assay for severity prediction and outcome prognosis in patients with COVID-19: An observational multi-cohort study. <i>EClinicalMedicine</i> , 2022, 49, 101495.	3.2	17
54	No Rebound of Morbidity Following Intermittent Preventive Sulfadoxine-Pyrimethamine Treatment of Malaria in Infants in Gabon. <i>Journal of Infectious Diseases</i> , 2009, 200, 1658-1661.	1.9	15

#	ARTICLE	IF	CITATIONS
55	Breakdown in membrane asymmetry regulation leads to monocyte recognition of <i>P. falciparum</i> -infected red blood cells. <i>PLoS Pathogens</i> , 2021, 17, e1009259.	2.1	14
56	Impact of dexamethasone on SARS-CoV-2 concentration kinetics and antibody response in hospitalized COVID-19 patients: results from a prospective observational study. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1520.e7-1520.e10.	2.8	13
57	Cross-Variant Neutralizing Serum Activity after SARS-CoV-2 Breakthrough Infections. <i>Emerging Infectious Diseases</i> , 2022, 28, 1050-1052.	2.0	11
58	Characterization of antimicrobial use and co-infections among hospitalized patients with COVID-19: a prospective observational cohort study. <i>Infection</i> , 2022, 50, 1441-1452.	2.3	10
59	Continuous Non-Invasive Monitoring of Tidal Volumes by Measurement of Tidal Impedance in Neonatal Piglets. <i>PLoS ONE</i> , 2011, 6, e21003.	1.1	9
60	Current status of the clinical development and implementation of paediatric artemisinin combination therapies in Sub-Saharan Africa. <i>Wiener Klinische Wochenschrift</i> , 2011, 123, 7-9.	1.0	8
61	Brain magnetic resonance imaging in imported malaria. <i>Malaria Journal</i> , 2019, 18, 74.	0.8	8
62	Intravenous Artesunate for Imported Severe Malaria in Children Treated in Four Tertiary Care Centers in Germany. <i>Pediatric Infectious Disease Journal</i> , 2019, 38, e295-e300.	1.1	7
63	Pyronaridine: a new <i>old</i> ™ drug on the verge of entering the antimalarial armamentarium. <i>Expert Review of Anti-Infective Therapy</i> , 2011, 9, 393-396.	2.0	6
64	In vitro activity of antifungal drugs against <i>Plasmodium falciparum</i> field isolates. <i>Wiener Klinische Wochenschrift</i> , 2011, 123, 26-30.	1.0	6
65	Continuous Noninvasive Monitoring of Lung Recruitment during High-Frequency Oscillatory Ventilation by Electrical Impedance Measurement: An Animal Study. <i>Neonatology</i> , 2013, 103, 218-223.	0.9	6
66	Chronic oral ulceration and lip swelling after a long term stay in Guatemala: A diagnostic challenge. <i>Travel Medicine and Infectious Disease</i> , 2018, 23, 103-104.	1.5	6
67	Chronic airflow obstruction in Tanzania – a cross-sectional study. <i>BMC Pulmonary Medicine</i> , 2018, 18, 11.	0.8	6
68	Determinants of post-malarial anemia in African children treated with parenteral artesunate. <i>Scientific Reports</i> , 2019, 9, 18134.	1.6	6
69	The use of paediatric artemisinin combinations in sub-Saharan Africa: a snapshot questionnaire survey of health care personnel. <i>Malaria Journal</i> , 2011, 10, 365.	0.8	5
70	Prospective observational study on the pharmacokinetic properties of the Iruva ribavirin regimen used in routine clinical practice in patients with Lassa fever in Nigeria. <i>BMJ Open</i> , 2020, 10, e036936.	0.8	4
71	Paediatric formulations of artemisinin-based combination therapies for treating uncomplicated malaria in children. <i>The Cochrane Library</i> , 2020, 12, CD009568.	1.5	3
72	Treatment of malaria in Austria: hazardous for patients or physicians?. <i>Wiener Klinische Wochenschrift</i> , 2009, 121, 598-598.	1.0	2

#	ARTICLE	IF	CITATIONS
73	Reply to Jaureguiberry et al. Clinical Infectious Diseases, 2016, 62, 271-271.	2.9	2
74	Paediatric Formulations of Artemisinin-Combination Therapies for Treating Uncomplicated Malaria in Children. The Cochrane Library, 2012, , .	1.5	1
75	Outpatient treatment of imported uncomplicated Plasmodium falciparum malaria: results from a survey among TropNet and GeoSentinel experts for tropical medicine. Journal of Travel Medicine, 2020, 27, .	1.4	1
76	Hookworm infection in returning travellers and migrants: a 10-year case series at a German center for tropical medicine. Journal of Travel Medicine, 2021, 28, .	1.4	1
77	In vitro screening identifies TRPV4 as target for endothelial barrier stabilization in COVID-19. FASEB Journal, 2021, 35, .	0.2	1
78	<i>In Vitro</i> Screening Identifies TRPV4 and PAR1 as Targets for Endothelial Barrier Stabilization in COVID-19. FASEB Journal, 2022, 36, .	0.2	1
79	Pyronaridine-artesunate retreatment for malaria. Lancet Infectious Diseases, The, 2016, 16, 136-137.	4.6	0
80	Echocardiographic Evaluation of Right Ventricular (RV) Performance over Time in COVID-19-Associated ARDS—A Prospective Observational Study. Journal of Clinical Medicine, 2021, 10, 1944.	1.0	0
81	Treatment of Severe Malaria. , 2019, , 1-12.		0